Edwards Lifesciences Corp (EW)

From the record

Edwards Lifesciences Corp's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Edwards Lifesciences Corp's 10 filed years say what it did: revenue went from $3.0 billion in fiscal 2016 to $6.1 billion in fiscal 2025, up 8.3% a year; it rose in 8 of 9 years; the deepest fall was 15% from fiscal 2021 to fiscal 2022; net income was positive in 5 of 5 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Edwards Lifesciences Corp's diluted share count shrank about 2.1% a year, and dividends and buybacks returned about 97% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 55 sales (33 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-10 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Edwards Lifesciences Corp earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 35 cents per dollar of everything the company owns. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count shrank 2.3% over the year (the filed statements).

From the record

Edwards Lifesciences Corp's standing among 26 graded names in its industry family: revenue of $6.1 billion in fiscal 2025 ranks in the top 13% by size; a net margin of 17.6% ranks in the top 6%; revenue growth of 10.8% a year over the last 3 filed years ranks in the top 31% (its annual reports).

From the record

Edwards Lifesciences Corp's leadership, from its insiders' filings and its current reports: the chief executive on the record is Zovighian, Bernard J (CEO, as filed), filing under that title since 2023-08-01, 3.3 years (top 44% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 7.5 years (top 22%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (top 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Edwards Lifesciences Corp's room to grow, from the newest filed statements (fiscal 2025): cash of $2.9 billion against debt of $598 million leaves 17.1% of its assets as net cash, top 43% of its family; cash from operations less capital spending is 22% of revenue (top 6%); a gross margin of 78% (top 6%); research spending of 17.8% of revenue (top 33%) (its annual report).

From the record

Edwards Lifesciences Corp's growth drivers, from the filed years to fiscal 2025: revenue grew 10.8% a year over the last three filed years against 8.3% over all 10, speeding up (top 42% of its family); the newest year grew 11.6% (top 26%); research spending grew 8.6% a year (top 35%); capital spending grew 2.1% a year (bottom 48%) (its annual reports). Edwards Lifesciences Corp reported 3 product lines in fiscal 2025: Transcatheter Aortic Valve Replacement at $4.5 billion (74%), Surgical Heart Valve Therapy at $1.0 billion (17%), Transcatheter Mitral and Tricuspid Therapies at $551 million (9%); 3 of 3 grew against the year before (its annual report).

From the record

Edwards Lifesciences Corp's newest year against its own record: revenue of $6.1 billion in fiscal 2025 came in 1.1% above the $6.0 billion its prior three years' pace pointed to (top 44% of its family); net income of $1.1 billion against a prior three-year average of $2.4 billion (bottom 28%); a net margin of 17.6% against 46.2% before (bottom 24%) (its annual reports).